| Literature DB >> 19703926 |
Anisur Rahman Khuda-Bukhsh1, Susanta Roy-Karmakar, Antara Banerjee, Pathikrit Banerjee, Surajit Pathak, Surjyo Jyoti Biswas, Saiful Haque, Debarsi Das, Naoual Boujedaini, Philippe Belon.
Abstract
In continuation of our short-term pilot studies reported earlier, results on certain toxicity biomarkers in volunteers who continued to take the potentized Arsenicum album 200C till 2 years are presented. Out of some 130 "verum"-fed volunteers of pilot study, 96 continued to take the remedy till 6 months, 65 till 1 year and 15 among them continued till 2 years. They provided samples of their urine and blood at 6 months, 1 year and finally at 2 years. None out of 17 who received "placebo" turned up for providing blood or urine at these longer intervals. Standard methodologies were used for determination of arsenic content in blood and urine, and for measurement of toxicity biomarkers like acid and alkaline phosphatases, alanine and aspartate amino transferases, lipid peroxidation and reduced glutathione and anti-nuclear antibody titers. Most of the volunteers reported status quo maintained after the improvement they achieved within the first 3 months of homeopathic treatment, in respect of their general health and spirit, and appetite and sleep. A few with skin symptoms and burning sensation, however, improved further. This was supported by the data of toxicity biomarkers, levels of all of which remained fairly within normal range. Therefore, administration of Arsenicum album 200C considerably ameliorates symptoms of arsenic toxicity on a long-term basis, and can be recommended for interim use, particularly in high risk remote villages lacking modern medical and arsenic free drinking water facilities. Similar studies by others are encouraged.Entities:
Year: 2011 PMID: 19703926 PMCID: PMC3094698 DOI: 10.1093/ecam/nep122
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Patient showing typical skin symptoms on soles before drug (BD) and after 2 months and 1 year of administration (after drug, AD) of Arsenicum album.
Figure 2Patient showing typical skin symptoms on palms BD and after 2 months and 1 year of administration (AD) of Arsenicum album.
Figure 3Patient showing typical skin symptoms on lips BD and after 2 months and 1 year of administration (AD) of Arsenicum album.
Figure 4Patient showing typical skin symptoms on soles BD and after 2 months and 1 year of administration (AD) of Arsenicum album.
Figure 5Patient showing hyper-pigmentation on hands BD and after 2 months and 1 year of administration (AD) of Arsenicum album.
Figure 6(a) Arsenic content in urine and blood of subjects fed Arsenicum album 200C; **P < .01, ***P < .001. (b) AcP activity in subjects fed Arsenicum album 200C against negative control; **P < .01, ****P < .001. (c) AlkP activity in subjects fed Arsenicum album 200C against negative control; **P < .01, ***P < .001. (d) AST activity in subjects fed Arsenicum album 200C against negative control; **P < .01, ***P < .001. (e) ALT activity in subjects fed Arsenicum album 200C against negative control; **P < .01, ***P < .001. (f) LPO in subjects fed Arsenicum album 200C against negative control; **P < .01, ***P < .001. (g) GSH content in subjects fed Arsenicum album 200C against negative control; **P < .01, ***P < .001.
ANA titer of blood sera of subjects fed Arsenicum album 200C against negative control
| Age group | Arsenic-contaminated villages | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (years) | Padumbasan | BD | AD (6 months) | AD (1 year) | ||||||||||||||||||||
| (negative control village) | ||||||||||||||||||||||||
| Male | Female | Male | Female | Male | Female | Male | Female | |||||||||||||||||
| Positive | B | Negative | Positive | B | Negative | Positive | B | Negative | Positive | B | Negative | Positive | B | Negative | Positive | B | Negative | Positive | B | Negative | Positive | B | Negative | |
| <20 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 1 | 10 | 3 | 1 | 3 | 0 | 0 | 18 | 0 | 0 | 5 | 1 | 0 | 7 | 2 | 0 | 1 |
| 20–40 | 0 | 0 | 18 | 1 | 0 | 0 | 17 | 5 | 16 | 9 | 1 | 12 | 1 | 0 | 30 | 0 | 0 | 17 | 2 | 0 | 14 | 1 | 1 | 8 |
| >40 | 0 | 0 | 5 | 0 | 0 | 2 | 9 | 2 | 12 | 7 | 1 | 10 | 1 | 0 | 25 | 0 | 0 | 16 | 4 | 1 | 19 | 1 | 2 | 8 |
Statistical analyses through one-way ANOVA of As content in urine and blood between before and after administration of verum groups at 0.05 and 0.001% levels
| Sum of squares | df | Mean square |
| Sig. | |
|---|---|---|---|---|---|
| As in urine 0.05% | |||||
| Between groups | 606 344.931 | 3 | 202 114.977 | 7.577 | 0.000 |
| Within groups | 7 335 673.459 | 275 | 26 675.176 | ||
| Total | 7 942 018.390 | 278 | |||
| As in urine 0.001% | |||||
| Between groups | 606 344.931 | 3 | 202 114.977 | 7.577 | 0.000 |
| Within groups | 7 335 673.459 | 275 | 26 675.176 | ||
| Total | 7 942 018.390 | 278 | |||
| As in Blood 0.05% | |||||
| Between groups | 224 260.499 | 3 | 74 753.500 | 12.834 | 0.000 |
| Within groups | 1 724 044.813 | 296 | 5 824.476 | ||
| Total | 1 948 305.312 | 299 | |||
| As in Blood 0.001% | |||||
| Between groups | 224 260.499 | 3 | 74 753.500 | 12.834 | 0.000 |
| Within groups | 1 724 044.813 | 296 | 5824.476 | ||
| Total | 1 948 305.312 | 299 |
Statistical analyses through one-way ANOVA of AcP, AIkP, AST, ALT, LPO and GSH between before and after administration of verum groups at 0.05 and 0.001% levels
| Sum of squares | df | Mean square |
| Sig. | |
|---|---|---|---|---|---|
| Acp 0.05% | |||||
| Between groups | 608.154 | 3 | 202.718 | 32.805 | 0.000 |
| Within groups | 1841.459 | 298 | 6.179 | ||
| Total | 2449.613 | 301 | |||
| Acp 0.001% | |||||
| Between groups | 608.154 | 3 | 202.718 | 32.805 | 0.000 |
| Within groups | 1841.459 | 298 | 6.179 | ||
| Total | 2449.613 | 301 | |||
| AlkP 0.05% | |||||
| Between groups | 268.420 | 3 | 89.473 | 54.706 | 0.000 |
| Within groups | 487.386 | 298 | 1.636 | ||
| Total | 755.806 | 301 | |||
| AlkP 0.001% | |||||
| Between groups | 270.590 | 3 | 90.197 | 55.974 | 0.000 |
| Within groups | 480.201 | 298 | 1.611 | ||
| Total | 750.791 | 301 | |||
| AST 0.05% | |||||
| Between groups | 90.025 | 3 | 30.008 | 25.388 | 0.000 |
| Within groups | 345.143 | 292 | 1.182 | ||
| Total | 435.168 | 295 | |||
| AST 0.001% | |||||
| Between groups | 25.800 | 3 | 8.600 | 23.974 | 0.000 |
| Within groups | 105.103 | 293 | .359 | ||
| Total | 130.903 | 296 | |||
| ALT 0.05% | |||||
| Between groups | 90.025 | 3 | 30.008 | 25.388 | 0.000 |
| Within groups | 345.143 | 292 | 1.182 | ||
| Total | 435.168 | 295 | |||
| ALT 0.001% | |||||
| Between groups | 90.025 | 3 | 30.008 | 25.388 | 0.000 |
| Within groups | 345.143 | 292 | 1.182 | ||
| Total | 435.168 | 295 | |||
| LPO 0.05% | |||||
| Between groups | 5.703 | 3 | 1.901 | 79.314 | 0.000 |
| Within groups | 6.951 | 290 | 2.397 | ||
| Total | 12.654 | 293 | |||
| LPO 0.001% | |||||
| Between groups | 5.686 | 3 | 1.895 | 78.813 | 0.000 |
| Within groups | 6.950 | 289 | 2.405 | ||
| Total | 12.636 | 292 | |||
| GSH 0.05% | |||||
| Between groups | 3833.749 | 3 | 1277.916 | 27.127 | 0.000 |
| Within groups | 13802.670 | 293 | 47.108 | ||
| Total | 17636.419 | 296 | |||
| GSH 0.001% | |||||
| Between groups | 3833.749 | 3 | 1277.916 | 27.127 | 0.000 |
| Within groups | 13 802.670 | 293 | 47.108 | ||
| Total | 17 636.419 | 296 |